Canada - English - Health Canada

endo ventures ltd. - tapentadol (tapentadol hydrochloride) - tablet (extended-release) - 50mg - tapentadol (tapentadol hydrochloride) 50mg - opiate agonists

Canada - English - Health Canada

endo ventures ltd. - tapentadol (tapentadol hydrochloride) - tablet (extended-release) - 100mg - tapentadol (tapentadol hydrochloride) 100mg - opiate agonists

Canada - English - Health Canada

endo ventures ltd. - tapentadol (tapentadol hydrochloride) - tablet (extended-release) - 150mg - tapentadol (tapentadol hydrochloride) 150mg - opiate agonists

Canada - English - Health Canada

endo ventures ltd. - tapentadol (tapentadol hydrochloride) - tablet (extended-release) - 200mg - tapentadol (tapentadol hydrochloride) 200mg - opiate agonists

Canada - English - Health Canada

endo ventures ltd. - tapentadol (tapentadol hydrochloride) - tablet (extended-release) - 250mg - tapentadol (tapentadol hydrochloride) 250mg - opiate agonists

United States - English - NLM (National Library of Medicine)

actavis pharma, inc. - hydromorphone hydrochloride (unii: l960up2krw) (hydromorphone - unii:q812464r06) - hydromorphone hydrochloride 8 mg - hydromorphone hydrochloride extended-release tablets are indicated for the management of pain in o p i o i d - t o l e r a n t  patients severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. patients considered opioid tolerant are those who are receiving, for one week or longer, at least 60 mg oral morphine per day, 25 mcg transdermal fentanyl per hour, 30 mg oral oxycodone per day, 8 mg oral hydromorphone per day, 25 mg oral oxymorphone per day, 60 mg oral hydrocodone per day, or an equianalgesic dose of another opioid. l i m i tat i o ns   of   u s e - because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses, and because of the greater risks of overdose and death with extended-release opioid formulations, reserve hydromorphone hydrochloride extended-release tablets for use in patients for whom  alternative treatment options (e.g., non-opioid analgesics or immediate-release opioids) are inef

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - tapentadol hydrochloride (unii: 71204kii53) (tapentadol - unii:h8a007m585) - tapentadol hydrochloride 50 mg - nucynta® (tapentadol) is indicated for the relief of moderate to severe acute pain in patients 18 years of age or older. enter section text here like other drugs with mu-opioid agonist activity, nucynta® is contraindicated in patients with significant respiratory depression in unmonitored settings or the absence of resuscitative equipment. nucynta® is also contraindicated in patients with acute or severe bronchial asthma or hypercapnia in unmonitored settings or the absence of resuscitative equipment [see warnings and precautions (5.1)] . like drugs with mu-opioid agonist activity, nucynta® is contraindicated in any patient who has or is suspected of having paralytic ileus. nucynta® is contraindicated in patients who are receiving monoamine oxidase (mao) inhibitors or who have taken them within the last 14 days due to potential additive effects on norepinephrine levels which may result in adverse cardiovascular events [see drug interactions (7.4)] . enter section text here pregnancy category c

United States - English - NLM (National Library of Medicine)

rebel distributors corp - tapentadol hydrochloride (unii: 71204kii53) (tapentadol - unii:h8a007m585) - tapentadol 50 mg - like other drugs with mu-opioid agonist activity, nucynta® is contraindicated in patients with significant respiratory depression in unmonitored settings or the absence of resuscitative equipment. nucynta® is also contraindicated in patients with acute or severe bronchial asthma or hypercapnia in unmonitored settings or the absence of resuscitative equipment [see warnings and precautions (5.1)] . like drugs with mu-opioid agonist activity, nucynta® is contraindicated in any patient who has or is suspected of having paralytic ileus. nucynta® is contraindicated in patients who are receiving monoamine oxidase (mao) inhibitors or who have taken them within the last 14 days due to potential additive effects on norepinephrine levels which may result in adverse cardiovascular events [see drug interactions (7.4)] . pregnancy category c. tapentadol hcl was evaluated for teratogenic effects in pregnant rats and rabbits following intravenous and subcutaneous exposure during the period of embryofetal organogenesis. w

United States - English - NLM (National Library of Medicine)

lake erie medical dba quality care products llc - tapentadol (unii: h8a007m585) (tapentadol - unii:h8a007m585) - tapentadol 50 mg - 1 indications and usage nucynta® (tapentadol) is indicated for the relief of moderate to severe acute pain in patients 18 years of age or older. 4 contraindications 4.1 impaired pulmonary function like other drugs with mu-opioid agonist activity, nucynta® is contraindicated in patients with significant respiratory depression in unmonitored settings or the absence of resuscitative equipment. nucynta® is also contraindicated in patients with acute or severe bronchial asthma or hypercapnia in unmonitored settings or the absence of resuscitative equipment [see warnings and precautions (5.1)] . 4.2 paralytic ileus like drugs with mu-opioid agonist activity, nucynta® is contraindicated in any patient who has or is suspected of having paralytic ileus. 4.3 monoamine oxidase inhibitors nucynta® is contraindicated in patients who are receiving monoamine oxidase (mao) inhibitors or who have taken them within the last 14 days due to potential additive effects on norepinephrine levels which ma

United States - English - NLM (National Library of Medicine)

stat rx usa llc - tapentadol hydrochloride (unii: 71204kii53) (tapentadol - unii:h8a007m585) - tapentadol hydrochloride 75 mg - like other drugs with mu-opioid agonist activity, nucynta® is contraindicated in patients with significant respiratory depression in unmonitored settings or the absence of resuscitative equipment. nucynta® is also contraindicated in patients with acute or severe bronchial asthma or hypercapnia in unmonitored settings or the absence of resuscitative equipment [see warnings and precautions (5.1)] . like drugs with mu-opioid agonist activity, nucynta® is contraindicated in any patient who has or is suspected of having paralytic ileus. nucynta® is contraindicated in patients who are receiving monoamine oxidase (mao) inhibitors or who have taken them within the last 14 days due to potential additive effects on norepinephrine levels which may result in adverse cardiovascular events [see drug interactions (7.4)] . pregnancy category c. tapentadol hcl was evaluated for teratogenic effects in pregnant rats and rabbits following intravenous and subcutaneous exposure during the period of embryofetal organogenesis. w